https://www.selleckchem.com/pr....oducts/alantolactone
The efficacy and safety of nanoparticle albumin-bound (nab)-paclitaxel combined with S-1 in patients with operable breast cancer is uncertain. We evaluated the feasibility of this combination followed by epirubicin/cyclophosphamide (EC) as neoadjuvant chemotherapy in such patients. This was an open-label, single-arm, phase II, single-institution prospective study of 4 cycles of nab-paclitaxel (260 mg/m ) administered intravenously on day 1 in combination with S-1 (65 mg/m orally twice daily) on days 1 to 14 every 21 days followed
Aimer
Commentaire
Partagez
